Meta-Analysis
Copyright ©The Author(s) 2024.
World J Clin Oncol. Jul 24, 2024; 15(7): 920-935
Published online Jul 24, 2024. doi: 10.5306/wjco.v15.i7.920
Table 1 Characteristics of the impact of tumor-infiltrating lymphocytes on the response to neoadjuvant therapy in triple-negative breast cancer patients included in the meta-analysis
Ref.
Data collection
Recruitment period
Sample size
Age in yr, median/mean (range)
TNM stage
Neoadjuvant regimen
Number of high/middle TILs as %, cut-off, and method
End point and pCR standard
Number of overall pCR as %
pCR rates as high TILs vs low TILs
OR or RR
Cerbelli et al[36], GermanyRetrospective consecutive cohort2011.6-2017.66150 (28-74)T1: 8; T2: 46; T3: 3; T4: 4; N0: 32; N1-N3: 29AC×4 (Q3W) →T×12 (QW)49 (17/32) (80.3), (50%) 10%, HEpCR, ypT023 (37.7)18 (36.7) vs 5 (41.7)OR: [U] 0.41 (0.17-0.95), 0.037; [M] 2.39 (0.96-5.96), 0.062
Galvez et al[17], PeruRetrospective cohort2003.1-2014.1243549 (24-84)II: 72, III: 363; AC×4 (Q3W) →T×12 (QW)181 (41.6), 50%, HE pCR, ypT046 (11.0)26 (14.4) vs 20 (7.9)NR
Abdelrahman et al[39], EgyptProspective cohort2017.1-2019.55045 (22-72)T1: 20; T2: 30; N0: 18; N1-N3: 32AC→T14 (28.0), 50%, HEpCR, ypT020 (40.0)10 (71.4) vs 10 (27.8)NR
Jung et al[53], KoreaRetrospective cohort2009.1-2014.12143NRT1-T2: 91; T3: 52; N0: 64; N1-N3: 79AC→T74 (51.7), 30%, HEpCR, ypT066 (46.2)43 (58.1) vs 23 (33.3)OR: [U] 2.774 (1.404-5.481), 0.003; [M] 3.484 (1.407-8.627), 0.007
Russo et al[47], VenezuelaRetrospective cohort2008-201341NRII: 80, III: 107;AC→T14 (34.1), 30%, HEpCR, ypT015 (36.6)11 (78.6) vs 4 (14.8)OR: [U] 8.85 (3.62-21.66), 0.001
Vicent et al[48], SpainRetrospective cohort1998-201516449 (29-81)II: 63, III: 37AC×4 (Q3W) →T×12 (QW)58 (35.4), 40%, HEpCR, ypT0/is, ypN061 (37.2)51 (88.0) vs 10 (9.0)NR
Ochi et al[32], JapanRetrospective consecutive cohort2001-20098052 (27-75)NRAC→T55 (19/36) (68.8), (50%) 10%, HEpCR, ypT025 (31.3)24 (43.6) vs 1 (4.0)NR
Bockstal et al[49], BelgiumRetrospective consecutive cohort2015.1-2020.33555.8 ± 13.3NRAC→T10 (28.6), 40%, HEpCR, ypT013 (37.1)8 (80.0) vs 5 (20.0)NR
Rangan et al[43], IndiaNRNR75NRT1-T3: 49; T4: 26; N0: 36; N1-N3: 39NR57 (76.0), 50%, HEpCR, ypT027 (36.0)25 (43.9) vs 2 (11.1)OR: [U] 6.25 (1.312-29.763), 0.025
Pang et al[18], ChiNRRetrospective cohort2010.1-2018.12310NRT1-2: 298; T3-4: 97AC→T177 (85/92) (57.1), (20%) 10%, HEpCR, ypT088 (28.4)53 (31.1) vs 33 (34.5)NR
Zhang et al[52], AmericaRetrospective cohort2005-20165846 (24-64)T1: 7; T2-T4: 51; N0: 30; N1-N3: 28AC×4 (Q3W) →T×12 (QW)17 (29.3), 60%, HEpCR, ypT026 (44.8)12 (70.6) vs 14 (34.1)NR
Zhao et al[50], ChiNRRetrospective cohort2017-201812650.1 ± 11.2T1: 78; T2-T3: 48; N0: 74; N1-N3: 52AC→T42 (33.3), 40%, HEpCR, ypT076 (60.3)38 (90.5) vs 38 (45.2)NR
Cerbelli et al[40], ItalyRetrospective consecutive cohort2011.1-2016.125450 (28-75)T1: 7; T2-T4: 47; N0: 24; N1-N3: 30AC×4 (Q3W) →T×12 (QW)22 (40.7), 50%, HEpCR, ypT0/is, N019 (35.2)11 (50.0) vs 8 (25.0)OR: [U] 1.61 (0.40-6.52), 0.025
Rao et al[30], ChiNRRetrospective consecutive cohort2009.7-2014.65246.9 (23-67)II: 34, III: 16;TAC21 (40.4), CD8: ≥ 0.15, HEpCR, ypT0 DFS OS14 (26.9)CD8: 10 (47.6) vs 4 (12.9) CD8 OR: [U] 6.14 (1.6-23.8), 0.010
Lusho et al[28], JapanRetrospective consecutive cohort2008-201912056 (28-86)NRTAC18 (15.0), 30%, HEpCR, ypT0/Tis ypN034 (28.3)10 (55.6) vs 24 (23.5)NR
Hida et al[37], JapanRetrospective cohort2007-20144856 (22-79)T1: 93; T2: 59; T3: 2; N0: 98; N1-N3: 56AC×4 (Q3W) →T×12 (QW)31 (11/20) (64.6), (50%) 10%, HEpCR, ypT0/is, ypN021 (43.8)18 (58.0) vs 3 (17.6)NR
Hida et al[27], JapanRetrospective consecutive cohort2007-201480NRN0: 56; N1-N3: 24TAC23 (28.8), 50%, HEpCR, ypT0/is, N028 (35.0)12 (52.2) vs 16 (28.1)NR
Kolberg et al[51], GermanyRetrospective cohortNR311NRNRAC→T59 (19.0), 60%, HEpCR, ypT0110 (35.4)35 (59.3) vs 75 (29.8)OR: [U] 3.44 (1.92-6.18), 0.001
Foldi et al[38], AmericaII RCT2015.12-2018.1154NRI: 12, II: 33, III: 14; T→ddAC- Durvalumab (3 and 10 mg/kg)26 (16/10) (48.1), (30%) 10%, HEpCR, ypT0/Tis ypN023 (42.6)15 (57.7) vs 8 (28.6)NR
Abuhadra et al[16], AmericaProspective cohort2015.10-2019.1131852.5 (24-77)I: 38, II: 210, III: 70; ddAC→T+ (Atezolizumab/ Panitumumab/ Bevacizumab)106 (33.3), 20%, HEpCR, ypT0130 (40.9)68 (64.2) vs 62 (29.2)NR
Denkert et al[33], GermanyRCT IPD pooled analysis2010.1-2016.12906NRNRT+ Bevacizumab646 (273/373) (71.3), (60%) 10%, HEpCR, ypT0333 (36.8)253 (39.2) vs 80 (30.8)NR
Yuan et al[34], AmericaII RCT2012.1-2018.86352 (28-79)II: 55, III: 12;TCb28 (6/22) (45.9), (60%) 10%, HEpCR, ypT030 (47.6)17 (60.7) vs 13 (39.3)Medium vs low1: OR: [U] 2.23 (0.74- 6.69), 0.16; high vs low1: OR: [U] 3.06 (0.49-9.30), 0.23
Sharma et al[46], AmericaII RCT2015.7-2018.510051 (29–70)T1: 19; T2: 70; T3-T4: 11; N0: 70; N1-N3: 30Arm-A: CbP + AC; Arm-B: CbD39 (43.3), 20%, HEpCR ypT0/is, ypN051 (56.7)26 (66.7) vs 25 (49.0)OR: [U] 2.08 (0.88-4.93), 0.096
Pons et al[45], SpainNR2016-202267NRT1-T2: 59; T3: 10; N0: 43; N1-N3: 26TCb + ddAC24 (35.8), 20%, HEpCR, ypT0/is, ypN036 (53.7)14 (58.3) vs 22 (51.2)NR
Abuhadra et al[15], AmericaNR2015.10-2020.1040851 (23–77)I: 41, II: 284, III: 83AC→TCb143 (35.0), 20%, HEpCR, ypT0/is, N0166 (40.7)85 (59.4) vs 81 (30.6)NR
Asano et al[31], JapanRetrospective cohort2007-201361NRT1: 24; T2-T4: 153; N0: 41; N1-N3: 136FEC→T48 (78.7), 10%, HEpCR, ypT028 (45.9)26 (54.2) vs 2 (15.4)NR
Ono et al[54], JapanNR1999-20079252 (23-76)II: 23, III: 36;AC→T
CEF
67 (72.8)1, high: (3-5), HEpCR, ypT029 (31.5)25 (37.3) vs 4 (16.0)NR
Wang et al[35], AmericaNR2007-201472NRT1: 5; T2: 48; T3: 15; T4: 5; N0: 38; N1-N3: 34NR53 (1/52) (73.6), (50%) 10%, HEpCR, ypT038 (52.8)35 (66.0) vs 3 (15.8)NR
Dong et al[29], ChiNRRetrospective cohort2010.1-2014.12170NRT1-2: 110; T3-4: 60TAC 122 (74/48) (71.8), (20%) 10%, HEpCR, ypT0 DFS OS48 (28.2)38 (31.1) vs 10 (24.8)NR
Würfel et al [44], GermanyNR2015.5-2017.4146NRT1: 59; T2-T4: 90NR24 (16.4), 50%, HEpCR ypT0 ypN056 (38.4)16 (66.7) vs 40 (32.8)NR
Hamy et al[42], FranceNR2015.1-2017.3717NRT1-T2: 529; T3: 189; N0: 282; N1-N3: 435NR81 (11.3), 50%, HEpCR, ypT0202 (28.2)48 (59.2) vs 154 (24.2)OR: [U] 5.02 (4.27-5.77), 0.001
Cerbelli et al[41], ItalyRetrospective consecutive cohortNR5949 (28-74)II: 36, III: 24NR17 (28.8), 50%, HEpCR, ypT022 (37.3)13 (76.5) vs 9 (21.4)NR